Foghorn Therapeutics (FHTX) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 9.7% versus a loss of 55.8%. Over five years, FHTX leads with a -83.9% price change compared with -84.7% for UNCY. Foghorn Therapeutics is the larger company by market cap ($118.2 million vs $111.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | UNCY |
|---|---|---|
| Share price | $1.99 | $4.07 |
| Market cap | $118.18M | $111.49M |
| 1-day change | -4.78% | -2.63% |
| YTD return | -63.15% | -27.56% |
| 1-year return | -55.78% | -9.72% |
| 5-year return | -83.93% | -84.65% |
| Forward P/E | — | 2.41 |
| EPS (TTM) | $-0.98 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $8.74 |
| 52-week low | $1.79 | $3.93 |
| Distance from 52-week high | -73.85% | -53.43% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +201.51% | +597.79% |
| Average volume | 629.61K | 839.29K |
| Shares outstanding | 59.39M | 27.39M |
| Employees | 106 | 21 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed FHTX by 46.1 percentage points over the past year.
- The two companies sit in different sectors: Foghorn Therapeutics in Health Care and Unicycive Therapeutics in Healthcare.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Healthcare · Biotechnology · 21 employees
FHTX vs UNCY FAQ
Which is bigger, Foghorn Therapeutics or Unicycive Therapeutics?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $118.18M compared with $111.49M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, FHTX or UNCY?
UNCY returned -9.72% over the past 12 months, compared with -55.78% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Unicycive Therapeutics in the same industry?
No. Foghorn Therapeutics is in the Health Care sector, while Unicycive Therapeutics is in Healthcare.